Publicaciones en colaboración con investigadores/as de Fundación Hospital Alcorcón (41)

2024

  1. Correction to: Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA (Scientific Reports, (2022), 12, 1, (13057), 10.1038/s41598-022-17271-3)

    Scientific Reports

  2. Digital Microscopy Augmented by Artificial Intelligence to Interpret Bone Marrow Samples for Hematological Diseases

    Microscopy and Microanalysis, Vol. 30, Núm. 1, pp. 151-159

  3. Glial cell activation precedes neurodegeneration in the cerebellar cortex of the YG8–800 murine model of Friedreich ataxia

    Neurobiology of Disease, Vol. 200

2023

  1. Anaphylaxis to European Perch (Perca fluviatilis) Due to a-Actin Protein

    Journal of investigational allergology & clinical immunology, Vol. 33, Núm. 2, pp. 143-144

  2. Role of Telomere Length in Survival of Patients with Idiopathic Pulmonary Fibrosis and Other Interstitial Lung Diseases

    Biomedicines, Vol. 11, Núm. 12

2022

  1. Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA

    Scientific Reports, Vol. 12, Núm. 1

  2. RICORS2040: The need for collaborative research in chronic kidney disease

    Clinical Kidney Journal, Vol. 15, Núm. 3, pp. 372-387

  3. Seroreactivity Against Tyrosine Phosphatase PTPRN Links Type 2 Diabetes and Colorectal Cancer and Identifies a Potential Diagnostic and Therapeutic Target

    Diabetes, Vol. 71, Núm. 3, pp. 497-510

2020

  1. Altered secretome and ros production in olfactory mucosa stem cells derived from friedreich’s ataxia patients

    International Journal of Molecular Sciences, Vol. 21, Núm. 18, pp. 1-22

2019

  1. A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia

    Haematologica, Vol. 104, Núm. 2, pp. 288-296

  2. Cannabidiol administration prevents hypoxia-ischemia-induced hypomyelination in newborn rats

    Frontiers in Pharmacology, Vol. 10, Núm. SEP

  3. aEEG and neurologic exam findings correlate with hypoxic–ischemic brain damage severity in a piglet survival model

    Pediatric Research, Vol. 85, Núm. 4, pp. 539-545

2018

  1. Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson's disease: Possible involvement of different binding sites at the PPARγ receptor

    Journal of Neuroinflammation, Vol. 15, Núm. 1

2017

  1. Neuroprotective effects of cannabidiol in hypoxic ischemic insult. The therapeutic window in newborn mice

    CNS and Neurological Disorders - Drug Targets, Vol. 16, Núm. 1, pp. 102-108

2016

  1. A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington’s disease

    Journal of Neurology, Vol. 263, Núm. 7, pp. 1390-1400

2015

  1. Endocannabinoids and Neurodegenerative disorders: Parkinson’s disease, Huntington’s chorea, Alzheimer’s disease, and others

    Handbook of Experimental Pharmacology (Springer New York LLC), pp. 233-259

2014

  1. A restricted population of CB1 cannabinoid receptors with neuroprotective activity

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 111, Núm. 22, pp. 8257-8262

  2. Changes in CB1 and CB2 receptors in the post-mortem cerebellum of humans affected by spinocerebellar ataxias

    British Journal of Pharmacology, Vol. 171, Núm. 6, pp. 1472-1489

2013

  1. Feasibility and safety of hospital discharge 24 hours after laparoscopic radical prostatectomy

    Archivos Espanoles de Urologia, Vol. 66, Núm. 10, pp. 931-938

  2. Resultados oncológicos en pacientes potencialmente candidatos a vigilancia activa sometidos a prostatectomía radical

    Actas Urologicas Espanolas, Vol. 37, Núm. 10, pp. 603-607